Samlyn Capital’s Exact Sciences EXAS Stock Holding History

Samlyn Capital’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-720,147	Closed	-$30.4M	–	99
2024 Q2	$30.4M	Buy	+720,147	New	+$39.6M	0.51%	57

Other funds holding EXAS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Samlyn Capital's EXAS Position: Q3 2024 in Review

Samlyn Capital sold out of Exact Sciences (EXAS) in Q3 2024, closing a stake of 720,147 shares — an estimated $30.4M sold.

Samlyn Capital first reported a position in EXAS in Q2 2024 and held it in 1 quarter. The position peaked at $30.4M in Q2 2024. 598 funds tracked by Wall St. Rank hold EXAS as of Q3 2024.

Samlyn Capital reported no remaining Exact Sciences position as of Q3 2024 after selling out during the quarter.
Samlyn Capital sold 720,147 Exact Sciences shares in Q3 2024, an estimated $30.4M.
Samlyn Capital first reported a position in Exact Sciences in Q2 2024 and held it in 1 quarter.
Samlyn Capital's Exact Sciences position peaked at $30.4M in Q2 2024.
598 funds tracked by Wall St. Rank held Exact Sciences as of Q3 2024.

Based on Samlyn Capital's 13F filing for Q3 2024, filed 14 Nov 2024.